Global Influenza Diagnostics Market

Influenza Diagnostics Market Size, Share, Growth Analysis, By Product (Test kit & Reagents, Instruments), By Test (Molecular Diagnostic Test, Transcription Mediated Amplification Based Assay), By End User, By Region - Industry Forecast 2025-2032


Report ID: SQSG35G2011 | Region: Global | Published Date: February, 2024
Pages: 165 | Tables: 62 | Figures: 75

Influenza Diagnostics Market Insights

Influenza Diagnostics Market size was valued at USD 1.1 Billion in 2023 and is poised to grow from USD 1.14 Billion in 2024 to USD 1.51 Billion by 2032, growing at a CAGR of 3.5% during the forecast period (2025-2032).

Increasing healthcare expenditure and the availability of effective treatment options have led to an increase in the median age worldwide. The WHO, CDC, and European Centre for Disease Prevention and Control, among other regulatory bodies, are actively recording incidence & prevalence data to counter the disease systematically. These bodies work together with local governments to achieve overall control of the treatment and management of this disease. The Global Influenza Program (GIP) is one initiative the WHO undertook to provide technical support, strategic guidance, and coordination activities concerning zoonotic, pandemic, and seasonal flu cases. Such initiatives are expected to boost Influenza Diagnostics market growth during the forecast period.

COVID- 19 has had a significant impact on the influenza diagnostics market across the globe. Many manufacturing facilities have ceased or closed because of the nation-wide lockdowns. Unfavorable regulations and guidelines changes of many disease diagnostics are hampering the flu diagnostic medium market. Supply chain disruptions in and responses to the spread of COVID- 19 are expected to have an impact. Besides, COVID- 19 and influenza have multiple things in common – Both of them are contagious viruses and also show similar symptoms of respiratory illness. Hence, it is mandatory to test for influenza, whenever COVID-19 affects the respiratory system of a patient. This is creating an increasing testing for influenza. 

US Influenza Diagnostics Market is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Influenza Diagnostics  Market size was valued at USD 1.3 billion in 2022 and is poised to grow from USD 1.4 billion in 2023 to USD 2.1 billion by 2031, growing at a CAGR of 4.9% during the forecast period (2024-2031). 

The Influenza Diagnostics market is undergoing greater regulatory scrutiny. Presently, companies spend considerable resources on clinical trials and submissions to meet regulatory requirements for diagnosing new tests. This may impose substantial pressure on the cost of developing novel influenza diagnostics technologies. Therefore, governments across the globe are developing regulations to manage the development and control the cost of testing. These regulations can significantly impact the things for the market and products will be affected for the development and adoption perspective. 'Thermo Fisher Scientific (US) ', 'Becton, Dickinson and Company (US) ', 'F. Hoffmann-La Roche AG (Switzerland) ', 'Hologic, Inc. (US) ', 'Abbott Laboratories, Inc. (US) ', 'DiaSorin (Italy) ', 'QIAGEN N.V. (Netherlands) ', 'Fujirebio Diagnostics, Inc. (Japan) ', 'Meridian Bioscience, Inc. (US) ', 'Luminex Corporation (US) ', 'Seegene Inc. (South Korea) ', 'Bio-Rad Laboratories, Inc. (US) ', 'Alere Inc. (US) ', 'GenMark Diagnostics, Inc. (US) ', 'Roche Diagnostics (Switzerland) ', 'BioMérieux SA (France) ', 'Cepheid (US) ', 'SD Biosensor (South Korea) ', 'Acon Laboratories, Inc. (US) ', 'Inverness Medical Innovations, Inc. (US)'

The rising global prevalence of influenza has surged the R&D activities for the accurate detection and diagnosis. Although the major concentration of research activities is targeted towards the development of a rapid and precise diagnosis of the influenza viruses, it will drive Influenza Diagnostics Market growth as well. In addition to this, the rising incidences of government initiatives against the outbreak of influenza, technological advancements, and the increasing incidences of cardiovascular diseases and diabetes will provide a further push to market growth. 

Increasing in the Reported Cases of Influenza: The global influenza diagnostics market is expected to experience growth due to the increased occurrence of influenza. According to the centers for disease control and prevention on average about 12,000- 79,000 people die of Influenza each year in the United States. The market is also expected to grow during the forecast period because of the increasing awareness of the importance of early detection and prevention of diseases such as influenza. 

North America is dominating the Influenza Diagnostics market with the largest market share. The North American region dominated the diagnostic market in 2023 which was mainly due to the government’s support for high-quality healthcare, increase in focus of influenza outbreak, and the high buying power. The U.S. was the largest revenue contributor to the North American market in 2023. This is mainly because the U.S. market is expected to grow due to the well-established healthcare infrastructure and increase in programs for influenza diagnostics. These factors are increasing the growth of the influenza diagnostics market in the North America region.   

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Influenza Diagnostics Market

Report ID: SQSG35G2011

$5,300
BUY NOW GET FREE SAMPLE